Drugs / SAR566658
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01156870 | Sep 2010 → Apr 2017 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02984683 | Mar 2017 → Sep 2018 | triple-negative breast carcinoma | Sanofi | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-10-20 | AbbVie | Results ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at AACR-NCI-EORTC Conference abbvie.com ↗
The data reported support that SAR566658 is generally well tolerated and can induce objective responses and sustained stable disease in heavily pretreated patients with CA6-positive cancers. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-10-20 | AbbVie | ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at AACR-NCI-EORTC Conference abbvie.com ↗ |
| 2010-09-21 | AbbVie | ImmunoGen, Inc. Announces Start of SAR566658 Clinical Testing abbvie.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR566658 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01156870 ↗ |
| Known as | huDS6-DM4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109635 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT01156870 ↗ |
| Target | MUC1 | “Mucin-1 binding agent” CHEMBL2109635 ↗ |